Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Showing results for "Au"

Research

The NICE-GUT trial protocol: A randomised, placebo controlled trial of oral nitazoxanide for the empiric treatment of acute gastroenteritis among Australian Aboriginal children

Diarrhoeal disease is the second leading cause of death in children under 5 years globally, killing 525 000 annually. Australian Aboriginal and Torres Strait Islander (hereafter Aboriginal) children suffer a high burden of disease.

Research

Optimising the use of linked administrative data for infectious diseases research in Australia

Increased collaboration and engagement across all sectors can optimise the use of linked data to help reduce the burden of infectious diseases

Research

Geographical disparities in emergency department presentations for acute respiratory infections and risk factors for presenting

One in four ED presentations in WA children are for ARIs, representing a significant out-of-hospital burden with some evidence of geographical disparity

Research

A novel technique of serial biopsy in mouse brain tumour models

Here we describe a method by which serial biopsy can be used to validate response to dacomitinib treatment in vivo using a mouse glioblastoma model

Research

Australian Group on Antimicrobial Research surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of age

From 1 January 2020 to 31 December 2021, thirty-eight institutions across Australia submitted data to the Australian Group on Antimicrobial Resistance (AGAR) from patients aged < 18 years (AGAR-Kids). Over the two years, 1,679 isolates were reported from 1,611 patients. This AGAR-Kids report aims to describe the population of children and adolescents with bacteraemia reported to AGAR and the proportion of resistant isolates.

Research

SeqNextGen: Translating NextGen Sequencing for the Diagnosis of Developmental Anomalies and Rare Diseases

Development and implementation of a person-centric Model of Care for people living with developmental anomalies and rare diseases in Western Australia.

Research

Searching for Strep A in the clinical environment during a human challenge trial: a sub-study protocol

Streptococcus pyogenes (also known as group A Streptococcus , Strep A) is an obligate human pathogen with significant global morbidity and mortality. Transmission is believed to occur primarily between individuals via respiratory droplets, but knowledge about other potential sources of transmission via aerosols or the environment is limited. Such knowledge is required to design optimal interventions to control transmission, particularly in endemic settings.

Research

Transmission potential of Streptococcus pyogenes during a controlled human infection trial of pharyngitis

Controlled human infection (CHI) models can provide insights into transmission of pathogens such as Streptococcus pyogenes (Strep A). As part of the Controlled Human Infection with Penicillin for Streptococcus pyogenes (CHIPS) trial, we explored the potential for transmission among participants deliberately infected with the Strep A emm75 strain.

Research

Aboriginal Urban Healthy Skin study

Asha Brad Glenn Jonathan Marianne Tim Bowen Farrant Pearson Carapetis AM Mullane Barnett BA MBBS DCH FRACP PhD GAICD FAHMS OAM BSc (Hons), PhD BA (

Research

Accelerate-WA Network: Developing a sustainable family-clinician-researcher network for education and training in the early detection of cerebral palsy for all infants in Western Australia

Accelerate will develop and pilot, a multi-directorate teaching and training network for early detection of cerebral palsy (CP), encompassing key clinical partners across CAHS and WACHS.